Kornimate/medical-research-clean huggingface dataset:
activity monitoring and counseling in a geriatric population

Conditions: Overweight; Obesity

Summary: the goal of the study is to determine if a fitbit, a kind of accelerometer, provides feedback to subjects combined with an activity counseling program will result in an increase in physical activity of at least 20%.


Eligibility criteria:
inclusion criteria * volunteers from the public including subjects in the independent living section of assisted living facilities between the ages of 65 and 85. * those over 85 may participate with their personal physician's consent. * bmi 25-40 kg/m2 or a waist circumference 88 cm or greater in women or 102 cm or greater in men * sedentary (no more than 30 minutes of vigorous or 90 minutes of moderate activity per week) * complete a timed get up and go test in \<= 20 seconds * if walking is done with an assistive device, the subject must have no history of falling with the use of said device) * subjects will complete the physical activity readiness questionnaire - revised (parq-r) which is as follows: 1. has your doctor ever said that you have a heart condition and that you should only do physical activity recommended by a doctor? 2. do you feel pain in your chest when you do physical activity? 3. in the past month, have you had chest pain when you were not doing physical activity? 4. do you lose your balance because of dizziness, or do you ever lose consciousness? 5. do you have a bone or joint problem that could be made worse by a change in your physical activity? 6. is your doctor currently prescribing drugs (for example, water pills) for your blood pressure or heart condition? 7. do you know of any other reason why you should not do physical activity? subjects who respond "yes" to any of the above questions will require written permission from their physician to participate in this study. exclusion criteria: * significant cognitive impairment (score on mini-cog less than 3). * diabetics on medication * subjects who should not participate in an exercise program will not be eligible for the study. * angina or a history of myocardial infarction * cancer (other than non-melanoma skin cancer) will not be eligible. * uncompensated liver disease * uncompensated thyroid disease * severe osteoporosis * any medical condition which might lead to weight loss or weight gain * patients on the following medications: antidepressants (those on bupropion and stable doses of selective serotonin re-uptake inhibitors (ssris) and trazodone will be included), antipsychotics, topiramate, orlistat, or phentermine (patients on statins will be eligible if no change in their medication is planned over the next 6 months)

Keywords: activity level overweight obesity
identification of carotid plague vulnerability by contrast enhanced ultrasound: correlation with plague histopathology

Conditions: Carotid Artery Plaque; Ultrasonic Diagnosis

Summary: objective/background: intraplaque neovascularization is one of the most important risk factors for unstable carotid plaque. this study was designed to evaluate whether carotid intraplaque neovascularization (ipn) can be accurately assessed by contrast enhanced ultrasound (ceus). methods: preoperative ceus analysis of 50 carotid artery stenosis patients would be compared to histopathology performed on their plaques excised by carotid endarterectomy (cea) with cd34 and mmp9 staining.

1. to enroll 50 cases of patients suffering from carotid artery stenosis continuously, the investigators perform contrast enhanced ultrasound on patients for identifying the vulnerable plagues and taking high resolution mr inspection to analysis those plagues at the same time. 2. all patients undergo carotid endarterectomy. the vulnerable ingredients of carotid plaques such as intraplaque neovascularization and bleeding are identified by pathological examination and immunohistochemical staining. 3. to evaluate the accuracy of ceus for identifying carotid vulnerable plague compared with high resolution mr. 4. the investigators divide patients into the stable group and the vulnerable group based on the results of ceus inspection. to analysis the incidence of postoperative complications such as stroke and mortality within 30 days and to compare the differences between the two groups.

Eligibility criteria:
inclusion criteria: * the patients with ischemic symptom whose carotid stenosis were more than 50% * the patients without ischemic symptom whose carotid stenosis were more than 70% exclusion criteria: * confirmed with severe intracranial vascular lesions * suffering from the large area cerebral infarction or critical stroke sequela * restenosis after cea or cas * suffering from severe coronary heart disease, respiratory failure,the hypertension difficult to controled * patients with malignant tumor or expected life \< 2 years

Keywords: carotid artery plaque contrast enhanced ultrasound plague histopathology
clinical controlled study on the efficacy of denosumab in treating osteoporosis in the domestic population and its impact on sarcopenia-related outcomes

Conditions: Sarcopenia; Osteoporosis; Denosumab

Summary: through the method of a clinical randomized controlled trial, patients meeting the study criteria are randomly assigned to either the denosumab treatment group or a placebo group. after a treatment period of 12 months, the differences in osteoporosis and sarcopenia-related baseline assessment changes between the two groups are compared. this is to explore the effect of denosumab in treating osteoporosis and its impact on sarcopenia. the goal is to evaluate the efficacy of denosumab in treating osteoporosis in the domestic population and its related impact on sarcopenia, with the aim of providing an effective treatment option for the domestic population suffering from 'osteoporosis-sarcopenia syndrome.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of postmenopausal/senile osteoporosis after examination and assessment. * clinical diagnosis of postmenopausal/senile osteoporosis combined with sarcopenia after examination and assessment. * have not previously taken any other anti-osteoporosis drugs. exclusion criteria: * clinical diagnosis of pathological fractures. * have participated in another clinical trial within the past 3 months or have taken other anti-osteoporosis drugs within the past 6 months. * severe chronic metabolic diseases or serious organ failure.
a study to evaluate long term safety and efficacy of recombinant human pentraxin-2 (rhptx-2; prm-151) in participants with idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this study will evaulate the long-term safety, efficacy and pharmacokinetics (pk) of recombinant human pentraxin-2 (rhptx-2; prm-151) zinpentraxin alfa, administered by intravenous (iv) infusion to participants with idiopathic pulmonary fibrosis (ipf).

this study is being conducted for the treatment of eligible participants who have taken part in study prm-151-202 and received the open-label study drug or completed the phase iii study wa42293 with prm-151. participants who have discontinued treatment from or have completed study wa42293 and do not want to receive prm-151 in this study, will be invited to enroll in survival follow-up.

Eligibility criteria:
inclusion criteria: * taken part in either of the prior prm-151 studies: prm-151-202 or wa42293. * for women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception. * for men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm. exclusion criteria: * acute respiratory or systemic bacterial, viral, or fungal infection at the first visit of the ole, or within 2 weeks of the first visit for patients joining cohort a (from study prm-151-202). * history of smoking within 3 months prior to the first visit in the ole. * history of alcohol or substance use disorder within 2 years prior to the first visit of the ole or known or suspected active alcohol or substance-use disorder. * history of severe allergic reaction or anaphylactic reaction to prm-151. * clinically significant abnormality on ecg during eligibility assessment that, in the opinion of the investigator, may pose an additional risk in administering study drug to the participant. * prolonged corrected qt interval \> 450 ms (for men) or \> 470 ms (for women) based on the fridericia correction formula. * clinically significant laboratory test abnormalities (hematology, serumchemistry, and urinalysis) that, in the opinion of the investigator, may pose an additional risk in administering study drug to the participant.
feasibility testing of patient reported outcomes - informed symptom management system (prisms)

Conditions: Colorectal Cancer; Bladder Cancer; Ovarian Cancer; Cervical Cancer; Uterine Cancer

Summary: this is a proof-of-concept pilot randomized clinical trial to test the feasibility of the innovative patient-reported outcomes-informed symptom management system (prisms) to enhance personalized supportive care for cancer patients and caregivers during post-treatment care transition.

in this proof-of-concept study, our multidisciplinary team will conduct a pilot randomized clinical trial to test the feasibility of the innovative patient-reported outcomes-informed symptom management system (prisms) to enhance personalized supportive care for cancer patients and caregivers during post-treatment care transition. we will randomly assign 21 cancer patients with newly created ostomies for cancer treatment with curative intent and their primary caregivers to the prisms or usual care groups (21 patient-caregiver dyads, a total of 42 individuals). prisms is defined as a personalized psychoeducational website including monitoring and personal feedback. we will conduct pre- and post-assessments of qol and pro (symptoms) at baseline upon enrollment and 2 months later.

Eligibility criteria:
inclusion criteria: patients must: * have been surgically treated for colorectal, bladder, ovarian, cervical, or uterine cancer with curative intent; * be within one month of hospital discharge of a newly created ostomy with curative intent; * be able to read and speak english; * be 18 years or older; * have a caregiver who is willing to participate in the study; caregivers must: * be 18 years or older; * be able to read and speak english; * be identified as the primary caregiver by the patient; * have not themselves been diagnosed with cancer or received cancer treatment during the study (to ensure that patients and caregivers focus their efforts on care of the patient). exclusion criteria: patients and their caregivers will be excluded if they: * are unable to read, speak, or understand english; * have more than one type of ostomy; * have other cancer diagnosis (excluding non-melanomatous skin cancer); or * have cognitive impairment (assessed by the short portable mental status questionnaire).

Keywords: ostomy (colostomy, urostomy, and ileostomy) symptom self-management caregiving family research telehealth self-efficacy quality of life post-treatment care transition
capacity of biofilm removal and gingival abrasion after utilization medium and soft toothbrushes

Conditions: Biofilm Removal; Gingival Abrasion

Summary: this study compared the removal of dental biofilm between soft and medium toothbrushes. the patients refrained from performing mechanical or chemical plaque control for 96 hours to allow dental biofilm accumulation on the tooth surfaces. after the period of dental biofilm formation, the quadrants were randomized and the participants brushed different quadrants with soft and medium toothbrushes, with or without dentifrice. the plaque indices were analyzed by a blinded examiner before and after toothbrushing. the 2tone was used for plaque disclosure and analysis was performed by the quigley-hein index modified by turesky et al. (1970).


Eligibility criteria:
inclusion criteria: * the study was conducted on 25 participants selected among undergraduate dental students of unifra (santa maria, rio grande do sul, brazil) * males and females * all systemically healthy * aged 18 to 30 years (mean age 21.4 ± 3.9 years) with at least 20 present teeth exclusion criteria: * the exclusion criteria comprised presence of sites with attachment loss ≥ 2mm * orthodontic appliances * prostheses * dental implants * aabrasions, restorations and/or carious lesions on the cervical region

Keywords: dental plaque gingival abrasion toothbrushing
therapy for depression with co-occurring panic or anxiety symptoms

Conditions: Depression; Anxiety Disorders; Panic Disorder

Summary: this 6-month study, with a 3-month follow up period, will compare the effectiveness of new and traditional psychotherapies for depression with panic or anxiety symptoms.

many depressed patients also experience significant symptoms of panic or anxiety. this study will compare the effectiveness of a new therapy called interpersonal psychotherapy for depression with panic or anxiety symptoms (ipt-ps) with that of traditional interpersonal psychotherapy for depression (ipt). participants are randomly assigned to receive up to 24 weeks of treatment with either ipt-ps or traditional ipt. improvements in interpersonal functioning, quality of life, and symptoms of depression and anxiety will be assessed at the end of therapy and at a 3-month follow-up.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of major depression with co-existing panic or anxiety symptoms. exclusion criteria: * history of manic episode(s). patients who have had hypomanic episodes in the past will be accepted into the study, provided they meet other admission criteria and are not presenting in a current hypomanic or mixed episode. * history of schizophrenia or schizoaffective disorder. * organic affective syndrome. * unspecified functional psychosis. * anorexia nervosa or bulimia nervosa. patients meeting criteria for an eating disorder not otherwise specified will not be excluded. * chronic drug or alcohol abuse/dependence within the past 2 years. patients with abuse related to episodes will not be excluded. * dsm-iv criteria for borderline or antisocial personality disorder. patients who meet criteria for other axis ii disorders will not be excluded. * inpatient treatment due to suicide risk or psychotic symptoms. * index episode secondary to the effect of medically prescribed drugs. * significant or untreated medical illness, including cardiovascular disorder, renal or liver disease, epilepsy, untreated hypertension, or unstabilized endocrine disease. * medical illness that would interfere with the best treatment strategy for the potential participant. * current treatment with an antidepressant. patients on a stable dose of anxiolytics for at least 3 months prior to study participation who are able to maintain this dosage throughout the study will not be excluded. * pregnant and breast-feeding women will be accepted into the study, but will not be prescribed adjunctive medications.

Keywords: mood disorders psychotherapy comorbidity
vulvovaginal candidiasis in canadian females

Conditions: Candidiasis, Vulvovaginal

Summary: vulvovaginal candidiasis (vvc; colloquially referred to as a 'yeast infection') is a prevalent mucosal infection caused by candida spp. that affects \~75% of women at least once in their life. vvc usually responds well to treatment, yet a small but significant fraction of women experience recurrent yeast infections even with weekly treatment. a further complication in understanding the causes of recurrent infections is that approximately one in five females have vaginal yeast present without any symptoms at any given point. the link between fungi, other microbes in the vagina ("microbiome"), and the human immune system remain poorly understood in the switch from having yeast present in the vagina without any symptoms and symptomatic yeast infections. fungi also compose a normal component of the microbiome at other sites in the body (e.g., oral, skin, gastrointestinal tract, rectum) where they may serve as a source of re-infection following treatment. in addition to the commonly prescribed 'first choice' antifungal drug fluconazole, a second-line treatment, boric acid, has shown promise in the literature and has been used locally with success at increasing the time between recurrent infections. a drawback of this therapy, however, is cost, as it is a compounded medication, and patients have to pay out of pocket. the purpose of this study is to understand how the yeast and bacterial microbial communities differ for females with recurrent infections from females with their first yeast infection and females with vaginal yeast present without any symptoms, and to track yeast diversity following treatment with either boric acid or fluconazole. the investigators hypothesize that they will identify multiple subpopulations of yeast at multiple anatomical body sites in females with vvc and recurrent vvc. they anticipate finding evidence for recurrent infection from secondary sites by linking genomic diversity of vaginal yeast strains during symptomatic infection to strains from other body sites. they hypothesize that yeast isolated from females with recurrent infections will exhibit different drug response phenotypes than yeast from females with asymptomatic vaginal yeast. they hypothesize that the vaginal microbiome of post-treatment patients treated with boric acid will differ from that of fluconazole. combined, they hypothesize that post-treatment response will differ between the drugs, indicating that treatment specifics influence the vaginal environment.


Eligibility criteria:
inclusion criteria: * female * between ages of 18 and 50 years. exclusion criteria: * currently pregnant * trying to get pregnant * have had a hysterectomy * bv infection
gold: brief intervention to reduce anxiety and promote resilience in families of youth with cancer

Conditions: Cancer

Summary: the purpose of this study is to examine a psychotherapeutic and psycho-educational intervention offered in virtual settings to caregivers of youth with cancer. human subjects must be used because they are the object of the intervention.

primary objective(s)- to examine the feasibility and accessibility of a brief intervention for caregivers of youth with newly-diagnosed cancer as a preliminary, data-generating step toward applying for a larger nci r34 grant evaluating the efficacy of the program in a randomized controlled trial. secondary objective(s)- we hope to learn whether a psycho-educational, psychotherapeutic intervention offered in a virtual setting to caregivers of children diagnosed with cancer is feasible, is acceptable, and can prevent, minimize, or improve symptoms of psychological distress (including symptoms of anxiety, depression, and post-traumatic stress disorder). we also hope to further our understanding of family stress and expand the idea for a need of mental health services in pediatric oncology. we aim to further understand intervention strategies for domains of family stress, reducing levels of caregiver anxiety, and promoting resilience for caregivers. this is important because these symptoms can affect the quality of life of caregivers and affect their ability to adhere to their children's treatments.

Eligibility criteria:
inclusion and exclusion criteria: parents inclusion * child (0-17yrs) with recent (\<12 mo) cancer diagnosis * fluent in english * consent to research exclusion: * lack of proficiency in written and spoken english * parent is under age 18 * active suicidal ideation * child with cancer does not provide assent inclusion and exclusion criteria: children inclusion: * recent (\<12 mo) cancer diagnosis in child * 8-17 years old * provides assent to participate in the study exclusion: * cannot read english * parent is not enrolled in the study anyone who is not a caregiver of children who have been diagnosed with cancer within the past 12 months will be excluded.

Keywords: any types of cancer
accuracy of cgm in the icu, compared to standard of care

Conditions: Diabetes

Summary: to determine the performance of the dexcom cgm device in comparison to arterial glucose samples.

the performance of the dexcom continuous glucose sensor will be compared with the current standard of care which is arterial glucose samples analyzed on a glucose meter. subjects will be icu patients receiving intravenous insulin infusions.

Eligibility criteria:
inclusion criteria: * minimum age 18 years * anticipated to be on an insulin infusion for 3-7 consecutive days * 10 of these subjects will be on vasopressors who will be receiving large volume fluid resuscitation exclusion criteria: * subjects not on insulin infusion

Keywords: insulin infusion continuous glucose sensor
extracellular vesicle micro rna profiling in congenital heart disease: fetal-maternal regulation in neonatal thrombosis

Conditions: Congenital Heart Disease; Single-ventricle; Thrombosis

Summary: newborns with congenital heart disease (chd) are at increased risk of developing postpartum and postoperative blood clots after cardiac surgery. the molecular mechanisms that are responsible for the clotting profile predisposing children to blood clots in the early stages of life are currently not well described. the goal of this proposal is to prospectively collect plasma samples from ten (10) neonates with antenatal diagnosis of severe congenital heart disease (chd) to better understand mechanisms responsible for abnormal clotting in the perioperative period.


Eligibility criteria:
inclusion criteria: * all neonates with a diagnosis of severe congenital heart disease undergoing surgery at boston children's hospital in the first week of life exclusion criteria: * none
multimodal, task-aware movement assessment and control: clinic to the home

Conditions: Frailty

Summary: the investigators seek to construct a novel, multimodal, distributed system that facilitates a new paradigm of home-based medical surveillance and treatment for frail older adults centered on timely diagnosis of movement system impairments and personalized intervention. measurements from a heterogeneous set of complementary sensors will be combined with clinically-informed and data-learned dynamic models of human motion to enable real-time activity recognition (e.g., sitting, standing, walking) and movement assessments (e.g., speed, repetition, quality). as the study progresses, the system will be integrated with wearable assistive technology to provide "smart", activity-specific assistance of movement deficits or the activation of caregivers if a decline in function is detected. finally, the investigators will test the combined assessment and intervention system in the clinic and the home, identifying challenges and solutions for the scaling up to unconstrained real-world settings.


Eligibility criteria:
inclusion criteria: * age \>= 18 years * capacity to consent * community dwelling * ability to follow 3-step commands * lives within 15 miles of boston exclusion criteria: * undomiciled * active substance use disorder * active psychosis * domestic violence or neglect * inability to communicate with investigators * other comorbidities that prevent full participation in the research
a study to examine the effect of reconval k1 cream to prevent skin toxicity from egfri

Conditions: Rash Due to Epidermal Growth Factor Receptor Inhibitors

Summary: vitamin k1 cream may prevent papulopustular rash induced by egfri given to metastatic colorectal cancer patients. this study will prospectively accrue metastatic colorectal patients receiving egfri and treat with reconval cream half face versus placebo cream half face to study whether vitamin k1 cream can prevent the typical skin eruption caused by egfri.


Eligibility criteria:
inclusion criteria: * metastatic colon cancer patients * male or female * age\> 18 * treated egfri exclusion criteria: * prior treatment with egfri

Keywords: egfri colon cancer skin toxicity reconval k1 cream